Under the agreement, Labcorp will manage Graves Gilbert's main full-service laboratory in Bowling Green, Kentucky and its facility in Glasgow, Kentucky.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Labcorp will acquire portions of the lab's clinical and women's health testing businesses, while MAWD will continue to provide anatomic and other pathology services.

Samples for the validation will be collected at the Catholic University of Korea and will represent people across all stages of Alzheimer's disease.

The deal for shares and cash is expected to close in the first half of 2025, and Sonic expects that it will be immediately accretive to earnings per share.

The system includes the Cobas I 601 analyzer and the first Ionify reagent pack of four assays for steroid hormones.

Last week, readers were most interested in a story about Gates Foundation awards to Detact Diagnostics to further develop a POC system and assays to detect infectious diseases.

The Diagnostics Development Services program is, so far, being used to help point-of-care testing firm Fluxergy bring to market a test for sexually transmitted infections.

Analyst Doug Schenkel said that Tempus has a broad and growing menu and Twist Bio has developed a novel DNA synthesis platform. He set $60 price targets for those companies.

Tracer has developed a proprietary platform for tumor-informed circulating-tumor DNA detection using digital PCR.

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.

The company's two tests will be gapfilled, meaning that Medicare contractors will determine pricing for the assays based on the firm's actual cost data.